Background: New modalities in the Endo Venous Laser Ablation (EVLA) include the new design of the laser catheter tip are claimed to distribute more effectively the laser beam to the targeted varicose vein (VV) wall and therefore to achieve better results and produce less complications. These favorable results support the previously suggested better outcome of the EVLA compared to the open procedure. Aim: This study was conducted to confirm this assumption. Patients and Methods: 81 patients scheduled for treatment of VV were included and were divided into 3 equal groups. EVLA was used with a bare tip fiber for the first group and compared to a second group treated with a radial fiber. Success rate and post-operative results of both groups were compared to each other, then the mean results of EVLA group as a whole was compared to a third control group treated by surgical stripping. Results: There was no statistical significant difference between both EVLA groups. One patient (3.7%), from the bare tip group, had incomplete ablation that necessitated surgical excision. Fewer complications, shorter hospital stay, early return to work and faster reduction in venous clinical severity score (VCSS) were noted among the EVLA compared to the open group. Conclusion: EVLA using bar tip or radial fibers are effective and safe in treating vv with similar results. Their results are as effective as the open procedure with shorter hospital stay, fewer complications and early return to work.

Background Dopamine D2 agonists are notable medications in the treatment of Parkinsonism, hyperprolactinemia, and hyperglycemia. An affiliation showed between the enlistment of myocardial injury ailment and long haul treatment with dopamine D2 agonist drugs identified with the partial initiation of 5-HT 2a receptors.Methods The investigation aims to represent the activity of sarpogrelate, a particular 5-HT (2A) receptor blocker, in diminishing myocardial injury prompted by extended haul utilization of D2 agonist drugs in diabetic rodents. Both bromocriptine and cabergoline managed independently and combined with sarpogelate for about a month to diabetic nephropathy rats.Results Bromocriptine and cabergoline created a significant reduction in BGL, BP, and kidney hypertrophy index in diabetic nephropathy rats. Administration of bromocriptine, cabergoline, alone, or in combination with sarbogrelate fundamentally diminished blood concentrations of ALP, AST, urea, and creatinine. Bromocriptine and cabergoline alone showed noteworthy ascending of LDH-1, Troponin I, and TNFα1 levels in the serum (p < 0.05). Paradoxically, utilizing bromocriptine and cabergoline with sarpogrelate treatment altogether diminished the degree of the myocardial biomarkers in the serum. A mix of bromocriptine or cabergoline with sarpogrelate diminished the level of the myocardial infarct size in the heart assessed utilizing the TTC staining method.Conclusions The examination exhibited that both bromocriptine and cabergoline could be utilized securely in blend with sarpogrelate for a long duration of treatment for diseases like hypertension and diabetes.

Background: The investigation aims to represent the activity of sarpogrelate, a particular 5-HT (2A) receptor blocker, in reducing myocardial injury prompted by extended haul utilization of D2 agonist drugs in diabetic rats. Dopamine D2 agonists are notable medications in the treatment of Parkinsonism, hyperprolactinemia, and hyperglycemia. An affiliation showed between the enlistment of myocardial injury ailment and long term treatment with dopamine D2 agonist drugs identified with the partial initiation of 5-HT 2a receptors. Methods: Both bromocriptine and cabergoline were managed independently and combined with sarpogelate for about a month to diabetic nephropathy rats. Both tail-cuff blood pressure and BGL were recorded weekly. For all animals, kidney hypertrophy index, serum creatinine, blood urea nitrogen, alanine transaminase, and aspartate transaminase levels were measured after one month of treatment. The severity of the cardiac injury was assessed by the estimation of LDH-1, cardiac troponin I, and TNFα. Triphenyl tetrazolium chloride staining method used to determine experimental myocardial infarction (MI) size. Results: Bromocriptine and cabergoline created a significant reduction in BGL, BP, and kidney hypertrophy index in diabetic nephropathy rats. Administration of bromocriptine, cabergoline, alone, or in combination with sarbogrelate fundamentally diminished blood concentrations of ALP, AST, urea, and creatinine. Bromocriptine and cabergoline alone showed noteworthy ascending of LDH-1, Troponin I, and TNFα1 levels in the serum (p<0.05). Paradoxically, utilizing bromocriptine and cabergoline with sarpogrelate treatment altogether diminished the degree of the myocardial biomarkers in the serum. A mix of bromocriptine or cabergoline with sarpogrelate diminished the level of the myocardial infarct size in the heart assessed utilizing the TTC staining method. Conclusions: The examination exhibited that both bromocriptine and cabergoline could be utilized safely in blend with sarpogrelate for a long duration of treatment for diseases like hypertension and diabetes.